{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:12:16Z","timestamp":1775023936247,"version":"3.50.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In recent years, as the availability of precision therapies expands, there is increasing reliance on genomic profiling assays to help identify the most appropriate treatment options for patients with advanced cancers. We retrospectively investigated the results of comprehensive genomic profiling tests from the time insurance coverage began until recently and examined the status of genetic analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively reviewed the analysis results of 300 patients with advanced solid tumors who consented to comprehensive genomic profiling tests from October 2019 to December 2022.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 300 patients who underwent comprehensive genomic profiling tests, analysis results for 274 patients were obtained, and were reviewed by the Clinical Genome Expert Panel. Six specimens (2%) were discontinued due to patient deaths and deteriorations in general condition. The three most frequently occurring actionable genomic alterations observed were TP53 (47.4%), KRAS (28.1%) and CDKN2A (20.4%). The most common druggable variant was CDKN2A, which was noted in 52 (19%) of 274 patients. The next most common were PIK3CA, BRAF, KRAS and PTEN. The cancer types that showed a greater median number of actionable alterations comprised thyroid cancer, pancreatic cancer and colorectal cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In conclusion, comprehensive genomic profiling tests have the potential to be valuable in identifying genomic abnormalities. Even if there is no effective treatment at present, it may lead to a treatment in the future. Comprehensive genomic profiling tests should be considered for any cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae128","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T12:52:39Z","timestamp":1726750359000},"page":"1298-1305","source":"Crossref","is-referenced-by-count":2,"title":["A single-institution retrospective study of comprehensive genomic profiling tests based on C-CAT findings for advanced solid cancers"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0617-0962","authenticated-orcid":false,"given":"Susumu","family":"Takeuchi","sequence":"first","affiliation":[{"name":"Department of Surgery, Tokyo Medical University , Tokyo,","place":["Japan"]},{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Tokyo Medical University Hospital , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sofuni","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Tokyo Medical University Hospital , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Ueda","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology , Head and Neck Surgery, , Tokyo,","place":["Japan"]},{"name":"Tokyo Medical University , Head and Neck Surgery, , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Umezu","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, Tokyo Medical University , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, Tokyo Medical University , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aoi","family":"Sukeda","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Tokyo Medical University , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Matsubayashi","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Tokyo Medical University , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Tokyo Medical University , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Bingo","sequence":"additional","affiliation":[{"name":"Clinical Genetics Center, Tokyo Medical University Hospital , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Clinical Genetics Center, Tokyo Medical University Hospital , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ohira","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tokyo Medical University , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Seike","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tokyo Medical University , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"2024121023185263600_ref1","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","article-title":"Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers","volume":"11","author":"Horak","year":"2021","journal-title":"Cancer Discov"},{"key":"2024121023185263600_ref2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jamaoncol.2020.7987","article-title":"Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors","volume":"1","author":"Cobain","year":"2021","journal-title":"JAMA Oncol"},{"key":"2024121023185263600_ref3","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: powering precision medicine through an international consortium","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov"},{"key":"2024121023185263600_ref4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/2159-8290.CD-20-1230","article-title":"St. Jude Cloud: a pediatric cancer genomic data-sharing ecosystem","volume":"11","author":"McLeod","year":"2021","journal-title":"Cancer Discov"},{"key":"2024121023185263600_ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PloS One"},{"key":"2024121023185263600_ref6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jjco\/hyac046","article-title":"Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system","volume":"52","author":"Higashigawa","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2024121023185263600_ref7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2022.11.003","article-title":"Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches","volume":"179","author":"Roggia","year":"2023","journal-title":"Eur J Cancer"},{"key":"2024121023185263600_ref8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s10038-022-01028-x","article-title":"Current status and issues related to secondary findings in the first public insurance covered tumor genomic profiling in Japan: multi-site questionnaire survey","volume":"67","author":"Minamoto","year":"2022","journal-title":"J Hum Genet"},{"key":"2024121023185263600_ref9","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","article-title":"C-CAT: the national datacenter for cancer genomic medicine in Japan","volume":"12","author":"Kohno","year":"2022","journal-title":"Cancer Discov"},{"key":"2024121023185263600_ref10","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3390\/cancers16081504","article-title":"Clinical and diagnostic utility of genomic profiling for digestive cancers: real-world evidence from Japan","volume":"16","author":"Ishikawa","year":"2024","journal-title":"Cancer"},{"key":"2024121023185263600_ref11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10147-020-01831-6","article-title":"Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1)","volume":"26","author":"Naito","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"2024121023185263600_ref12","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/cas.13265","article-title":"Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors","volume":"108","author":"Kou","year":"2017","journal-title":"Cancer Sci"},{"key":"2024121023185263600_ref13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13073-016-0387-8","article-title":"Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine","volume":"8","author":"Nagahashi","year":"2016","journal-title":"Genome Med"},{"key":"2024121023185263600_ref14","doi-asserted-by":"publisher","first-page":"7407","DOI":"10.1002\/cam4.3383","article-title":"Clinical implications of next-generation sequencing-based panel tests for malignant ovarian tumors","volume":"9","author":"Saotome","year":"2020","journal-title":"Cancer Med"},{"key":"2024121023185263600_ref15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.pan.2018.07.006","article-title":"Genomic testing for pancreatic cancer in clinical practice as real-world evidence","volume":"18","author":"Hayashi","year":"2018","journal-title":"Pancreatology"},{"key":"2024121023185263600_ref16","doi-asserted-by":"publisher","first-page":"PO.19.00291","DOI":"10.1200\/PO.19.00291","article-title":"Precision oncology and the universal health coverage system in Japan","volume":"3","author":"Ebi","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"2024121023185263600_ref17","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2024121023185263600_ref18","doi-asserted-by":"publisher","first-page":"13563","DOI":"10.1038\/srep13563","article-title":"Clinicopathological significance of CDKN2A promoter hypermethylation frequency with pancreatic cancer","volume":"5","author":"Tang","year":"2015","journal-title":"Sci Rep"},{"key":"2024121023185263600_ref19","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1097\/MPA.0000000000001888","article-title":"The role of inherited pathogenic CDKN2A variants in susceptibility to pancreatic cancer","volume":"50","author":"Kimura","year":"2021","journal-title":"Pancreas"},{"key":"2024121023185263600_ref20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12282-018-0894-0","article-title":"CDKN2A\/P16INK4A variants association with breast cancer and their in-silico analysis","volume":"26","author":"Aftab","year":"2019","journal-title":"Breast Cancer"},{"key":"2024121023185263600_ref21","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1200\/JCO.2017.74.8301","article-title":"Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data","volume":"36","author":"Zardavas","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024121023185263600_ref22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"13","author":"Lindeman","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2024121023185263600_ref23","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1200\/JCO.19.03010","article-title":"Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)","volume":"38","author":"Flaherty","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024121023185263600_ref24","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1634\/theoncologist.2016-0049","article-title":"Clinical actionability of comprehensive genomic profiling for management of rare or refractory cancers","volume":"21","author":"Hirshfield","year":"2016","journal-title":"Oncologist"},{"key":"2024121023185263600_ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266112","article-title":"Clinical utility of comprehensive genomic profiling in Japan: result of PROFILE-F study","volume":"17","author":"Aoyagi","year":"2022","journal-title":"PloS One"},{"key":"2024121023185263600_ref26","doi-asserted-by":"publisher","first-page":"djv332","DOI":"10.1093\/jnci\/djv332","article-title":"Prospective clinical study of precision oncology in solid tumors","volume":"108","author":"Sohal","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2024121023185263600_ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100336","article-title":"Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers","volume":"7","author":"Palmeri","year":"2022","journal-title":"ESMO Open"},{"key":"2024121023185263600_ref28","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2024121023185263600_ref29","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"2024121023185263600_ref30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/12\/1298\/60983229\/hyae128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/12\/1298\/60983229\/hyae128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T23:19:21Z","timestamp":1733872761000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/12\/1298\/7761960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,9,19]]},"published-print":{"date-parts":[[2024,12,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae128","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,9,19]]}}}